5-溴萘-1-甲酸 | 16726-67-3

• 物质功能分类: 化学试剂 - 有机试剂 - 多环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 5-溴萘-1-甲酸
• 中文别名: 5-溴-1-萘甲酸
• 英文名称: 5-bromo-1-naphthalenecarboxylic acid
• 英文别名: 5-bromo-1-naphthoic acid；5-bromonaphthalene-1-carboxylic acid
• CAS: 16726-67-3
• 化学式: C₁₁H₇BrO₂
• mdl: MFCD00092713
• 分子量: 251.079
• InChiKey: SZFXXNVLSUTKJF-UHFFFAOYSA-N

物化性质

• 熔点：
  261°C
• 沸点：
  421.2±18.0 °C(Predicted)
• 密度：
  1.5480 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-1-naphthoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-1-naphthoic acid
CAS number: 16726-67-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H7BrO2
Molecular weight: 251.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴萘-1-甲酸 在 sodium azide 、 硫酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-氨基-1-萘甲腈
  参考文献：
  名称：

  13C NMR 研究 5-取代 1-萘腈中的电子相互作用

  摘要：

  5-Z-取代的 1-萘腈（1；Z = H、F、Cl、Br、NH2、NMe2、CN、NO2、OMe、CHO、CO2Me）在氘氯仿和纯三氟乙酸中的碳 13 NMR 化学位移（ TFA) 报道。发现 CN 碳位移与双取代基参数 (DSP) 密切相关。DSP 相关性中传输系数的负值表明存在反向取代基电子效应，这与 CN 多重键的 π 极化变化有关，主要是由于各种 Z 的空间场效应的差异。由于偶极 ArC+ξN− 对共振杂化的更大贡献，在纯 TFA 中效果减弱 1。芳族碳位移与取代基化学位移加成性的偏差很小，然而，许多碳共振显示出不同的模式。中性溶剂和 TFA 中 C-1-CNipso 碳位移 1 的偏差与 DSP 大致相关。它们归因于 C-1 处电荷密度的变化，这是由取代基引起的 CN 键极性变化的结果。在 C-6 和 C-8 共振中观察到的屏蔽大于预期与 +R 取代基减少的电子撤出和给电子基团 Z

  DOI：

  10.1002/(sici)1097-458x(199604)34:4<301::aid-omr879>3.0.co;2-6
• 作为产物：
  描述：

  氰基萘 在 二硫化碳 、 sodium hydroxide 、 溴 作用下， 生成 5-溴萘-1-甲酸
  参考文献：
  名称：

  Hausamann, Chemische Berichte, 1876, vol. 9, p. 1519

  摘要：

  DOI：

文献信息

• [EN] HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE MER
  申请人：DONG A SOCIO HOLDINGS CO LTD

  公开号：WO2018071343A1

  公开（公告）日：2018-04-19

  Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式(I)的化合物及其药学上可接受的盐，其中A、R1、R2、R3、R4、R5、R6、R7、R24、X、L、n和p如规范中定义的那样，可用于治疗或预防Mer酪氨酸激酶受体调节的疾病或症状。还描述了式(I)的化合物的药物组合物，以及使用这些化合物和组合物的方法。
• 含噻吩酰胺结构衍生物、制备方法及其用途
  申请人：佛山市赛维斯医药科技有限公司

  公开号：CN108101884A

  公开（公告）日：2018-06-01

  本发明涉及医药领域，具体而言，本发明涉及一种含噻吩酰胺类结构的衍生物物、其制备方法以及在制备治疗炎症性疾病、眼科疾病及呼吸系统疾病等中的应用。其中，R选自C1‑C5的烷基，C3‑C6的环烷基。
• 一种含异丙胺和噻吩酰胺类结构的化合物
  申请人：佛山市赛维斯医药科技有限公司

  公开号：CN108191820A

  公开（公告）日：2018-06-22

  本发明涉及医药领域，具体而言，本发明涉及一种异丙胺和硝基噻吩酰胺类结构的化合物、其制备方法以及在制备治疗炎症性疾病、眼科疾病及呼吸系统疾病等中的应用。
• The Substituent Effect. XI. Solvolysis of 5-, 6-, and 7-Substituted 1-(1-Naphthylethyl) Chlorides
  作者：Yuho Tsuno、Masami Sawada、Takahiro Fujii、Yoshihiko Tairaka、Yasuhide Yukawa

  DOI：10.1246/bcsj.48.3356

  日期：1975.11

  Fourteen 5-, 6-, and 7-substituted 1-(1-naphthylethyl) chlorides were prepared and the solvolysis rates were determined in 80% (v/v) aqueous acetone at 45 °C. The effects of −R substituents at respective positions were treated on the basis of the equation, logk⁄k0=ρiσi+ρx+σx+=ρ(Cijσi+qrij+σπ+). The position dependency of the inductive effect was given by Cij(=ρi⁄ρi,4α); C3α=1.37, C4α=1.00, C5α=0.75, C6α=0.57, and C7α=0.72. The Cij values appear to be correlated with Dewar’s simplified field function 1/rij. The position dependency of Pi-electronic effect given by the ratio ρπ+⁄ρi,4α=qr·ij+ was consistent with the prediction from the MO indices, such as Forsyth’s Δqij(ArCH2+ parameters. The same treatment was applied also to three other naphthalene reactivities, detritiation, pKa of α-naphthoic acids and pKa of naphthylammonium ions. The linear ρi–ρi relation holds among these reactions, suggesting a reaction-independent scheme of the inductive transmission. The qr·ij+ values vary at conjugate positions with reaction but not at non-conjugate positions irrespective of reactions. The results are discussed in comparison with those of relevant treatments.

  制备了十四个5-、6-和7-取代的1-(1-萘乙基)氯化物，并在45°C下，80%（体积/体积）的乙酸水溶液中测定了其溶剂分解速率。基于方程logk⁄k0=ρiσi+ρx+σx+=ρ(Cijσi+qrij+σπ+)，处理了在相应位置上的−R取代基的影响。诱导效应的位置依赖性由Cij(=ρi⁄ρi,4α)给出；C3α=1.37，C4α=1.00，C5α=0.75，C6α=0.57，C7α=0.72。Cij值似乎与Dewar的简化场函数1/rij相关。由比率ρπ+⁄ρi,4α=qr·ij+给出的π电子效应的位置依赖性与从MO指数（如Forsyth的Δqij(ArCH2+参数）的预测一致。同样的处理也应用于其他三种萘的反应性：脱氢、α-萘甲酸的pKa和萘甲基铵离子的pKa。在这些反应中，线性ρi–ρi关系成立，表明诱导传递的反应独立方案。qr·ij+值在共轭位置随反应变化，但在非共轭位置不随反应变化。结果在与相关处理的比较中进行了讨论。
• [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
  申请人：Clark D. Jerry

  公开号：US20050043309A1

  公开（公告）日：2005-02-24

  This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R 1 , and R 4 through R 7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

  这项发明涉及公式1的化合物 其中G、D、A、Z、Q、X、Y、R 1 和R 4 至R 7 的定义如规范中所述，制备这些化合物的方法以及用于制备这些化合物的中间体，以及含有这些化合物的药物组合物及其在治疗中枢神经系统疾病和其他疾病中的用途。